NCT05301361
Sensitivity of the NIH Toolbox to Stimulant Treatment in Intellectual Disabilities
Enrolling by Invitation
PHASE1Ages 6–24InterventionalUniversity of California, DavisInvestigator-initiated
~68 participants
Updated 2025-12-15 on ClinicalTrials.gov
What's tested:Methylphenidate Oral Solution
At a glance
Recruiting sites
0 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Composite score of NIHTB-CB Flanker, Dimensional Change Card Sort, List Sorting and Speeded Matching tests.
Measured over 11 weeks
Conditions
Where it's being run
3 sites across 3 statesCalifornia1
Illinois1
Ohio1
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
IQ below 80
Mental age 3.0 or higher (Stanford Binet)
Diagnosis of Intellectual Disability
Diagnosis of ADHD
Ability to complete valid NIHTB-CB tests at screening/baseline
Exclusion
stimulant use within 2 weeks prior to randomization
history of a sensitivity reaction to stimulants
presence of significant comorbid psychiatric or medical disorder/illness deemed by the site physician as inappropriate for stimulant use (uncontrolled epilepsy, bipolar disorder, psychosis, severe OCD, hypertension, tachycardia hypertension, failure to thrive, psychosis for example)
a household resident with a current substance abuse disorder
What this trial measures
- Composite score of NIHTB-CB Flanker, Dimensional Change Card Sort, List Sorting and Speeded Matching tests.11 weeks
The composite score is calculated as the average of the non-age adjusted standard scores of each of these four tests. These standard scores have a mean of 100 and SD of 15. A minimum of 3/4 valid scores is required to calculate an average composite score.